Tags

Type your tag names separated by a space and hit enter

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Sep; 23(10):1367-1376.MS

Abstract

BACKGROUND

Alemtuzumab was superior on clinical and magnetic resonance imaging (MRI) outcomes versus subcutaneous interferon beta-1a in phase 3 trials in patients with relapsing-remitting multiple sclerosis.

OBJECTIVE

To examine quality-of-life (QoL) outcomes in the alemtuzumab phase 3 trials.

METHODS

Patients who were treatment naive (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I [CARE-MS I]) or had an inadequate response to prior therapy (CARE-MS II) received annual courses of alemtuzumab 12 mg/day at baseline (5 days) and Month 12 (3 days) or subcutaneous interferon beta-1a 44 µg three times/week. QoL was measured every 6 or 12 months using Functional Assessment of Multiple Sclerosis (FAMS), European Quality of Life-5 Dimensions (EQ-5D) and its visual analog scale (EQ-VAS), and 36-Item Short-Form Survey (SF-36).

RESULTS

Statistically significant improvements from baseline with alemtuzumab were observed on all three QoL instruments at the earliest post-baseline assessment and sustained through Year 2. Statistically significant greater QoL improvements over subcutaneous interferon beta-1a were seen at all time points in CARE-MS II with FAMS, EQ-VAS and SF-36 physical component summary, and in CARE-MS I with FAMS.

CONCLUSION

Patients treated with alemtuzumab had improvements in physical, mental, and emotional QoL regardless of treatment history. Improvements were significantly greater with alemtuzumab versus subcutaneous interferon beta-1a on both disease-specific and general measures of QoL.

Links

Publisher Full Text

Authors+Show Affiliations

Arroyo González R
Department of Neurology, Hospital Universitario Quirónsalud, Madrid, Spain.
Kita M
Virginia Mason Hospital & Seattle Medical Center, Seattle, WA, USA.
Crayton H
Multiple Sclerosis Center of Greater Washington, Vienna, VA, USA.
Havrdova E
MS Center, Department of Neurology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Margolin DH
Sanofi Genzyme, Cambridge, MA, USA.
Lake SL
Sanofi Genzyme, Cambridge, MA, USA.
Giovannoni G
Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
CARE-MS I and II Investigators
No affiliation info available

MeSH

AdultAlemtuzumabFemaleHumansImmunologic FactorsInterferon beta-1aMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingQuality of LifeTreatment Outcome

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27885061

Citation

Arroyo González, Rafael, et al. "Alemtuzumab Improves Quality-of-life Outcomes Compared With Subcutaneous Interferon Beta-1a in Patients With Active Relapsing-remitting Multiple Sclerosis." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 23, no. 10, 2017, pp. 1367-1376.
Arroyo González R, Kita M, Crayton H, et al. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler. 2017;23(10):1367-1376.
Arroyo González, R., Kita, M., Crayton, H., Havrdova, E., Margolin, D. H., Lake, S. L., & Giovannoni, G. (2017). Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 23(10), 1367-1376. https://doi.org/10.1177/1352458516677589
Arroyo González R, et al. Alemtuzumab Improves Quality-of-life Outcomes Compared With Subcutaneous Interferon Beta-1a in Patients With Active Relapsing-remitting Multiple Sclerosis. Mult Scler. 2017;23(10):1367-1376. PubMed PMID: 27885061.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. AU - Arroyo González,Rafael, AU - Kita,Mariko, AU - Crayton,Heidi, AU - Havrdova,Eva, AU - Margolin,David H, AU - Lake,Stephen L, AU - Giovannoni,Gavin, AU - ,, Y1 - 2016/11/25/ PY - 2016/11/26/pubmed PY - 2018/5/17/medline PY - 2016/11/26/entrez KW - Alemtuzumab KW - CD52 antigen KW - disease-modifying therapy KW - interferon beta-1a KW - multiple sclerosis KW - quality of life SP - 1367 EP - 1376 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult Scler VL - 23 IS - 10 N2 - BACKGROUND: Alemtuzumab was superior on clinical and magnetic resonance imaging (MRI) outcomes versus subcutaneous interferon beta-1a in phase 3 trials in patients with relapsing-remitting multiple sclerosis. OBJECTIVE: To examine quality-of-life (QoL) outcomes in the alemtuzumab phase 3 trials. METHODS: Patients who were treatment naive (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I [CARE-MS I]) or had an inadequate response to prior therapy (CARE-MS II) received annual courses of alemtuzumab 12 mg/day at baseline (5 days) and Month 12 (3 days) or subcutaneous interferon beta-1a 44 µg three times/week. QoL was measured every 6 or 12 months using Functional Assessment of Multiple Sclerosis (FAMS), European Quality of Life-5 Dimensions (EQ-5D) and its visual analog scale (EQ-VAS), and 36-Item Short-Form Survey (SF-36). RESULTS: Statistically significant improvements from baseline with alemtuzumab were observed on all three QoL instruments at the earliest post-baseline assessment and sustained through Year 2. Statistically significant greater QoL improvements over subcutaneous interferon beta-1a were seen at all time points in CARE-MS II with FAMS, EQ-VAS and SF-36 physical component summary, and in CARE-MS I with FAMS. CONCLUSION: Patients treated with alemtuzumab had improvements in physical, mental, and emotional QoL regardless of treatment history. Improvements were significantly greater with alemtuzumab versus subcutaneous interferon beta-1a on both disease-specific and general measures of QoL. SN - 1477-0970 UR - https://www.unboundmedicine.com/medline/citation/27885061/Alemtuzumab_improves_quality_of_life_outcomes_compared_with_subcutaneous_interferon_beta_1a_in_patients_with_active_relapsing_remitting_multiple_sclerosis_ L2 - https://journals.sagepub.com/doi/10.1177/1352458516677589?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -